CTIS2022-502254-13-00招募中1 期
Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial - S67130
Z Leuven0 个研究点目标入组 246 人开始时间: 2023年1月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 246
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures., Acinar adenocarcinoma (inclusive neuro-endocrine dedifferentiation)., Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as true secsual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)), use of condom or vasectomy or commitment to a partner using implants, injectables, combined oral contraceptives or some IUDs (27). This method of contraception needs to be continued for at least 6 months after the last dose of Trial treatment(s)., Oligoprogressive disease defined as a maximum of 5 extracranial progressive lesions (pre-existing lesions, the development of new lesions, or both) in any organ reported according to the PROMISE V2 Framework for the standardized reporting of PSMA PET for research and clinical routine. In case of locally persistent/recurrent disease, a diagnostic magnetic resonance imaging (MRI) or dedicated CT-scan should be performed. If a metastatis in the extremities is suspected, a bone scan or dedicated CT-scan will be performed. In case of locally persistent/recurrent disease, a diagnostic MRI of the prostate (bed) and/or biopsy of the site is recommended. There are two different mCRPC patient groups who are eligible for inclusion in the trial: a. Patients with oligoprogressive disease with pADT only as ongoing treatment (Type 1). b. Patients with oligoprogressive disease with pADT +/- second line systemic therapy. This is both the combination of pADT + ARTA as ongoing treatment or patients who had received docetaxel in the past (Type 2)., Castration-refractory disease, defined as testosterone level < 50 ng/dL or 1.7 nmol/L and the presence of biochemical or radiologic progression., Prior treatment of the primary tumor by radiotherapy or surgery. If the primary tumor had not been treated, local therapy should be added to the treatment together MDT., WHO performance 0-2, Age 18 years or older, Absence of psychological, sociological or geographical condition potentially hampering compliance with study protocol., Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board
排除标准
- •Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol, Ductal adenocarcinoma and small-cell prostate cancer, Spinal bone lesion that is highly symptomatic, neurologically threatening or at risk of fracture will be excluded., Patients with progressive disease while receiving docetaxel at the moment of progression., Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial., Participation in an interventional Trial with an investigational medicinal product (IMP) or device, Serum testosterone level > 50 ng/ml or 1.7 nmol/l., Presence of poly-progressive disease, defined as more than 5 progressive lesions on PSMA PET-CT including local recurrence, nodal disease and/or metastatic lesions., Active malignancy other than prostate cancer that could potentially interfere with the interpretation of this trial., Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible., Not able to understand the treatment protocol or sign informed consent., Patients already treated with radionuclides, cabazitaxel or PARP-inhibitors in the past.
研究者
相似试验
进行中（未招募）
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen.EUCTR2022-000066-18-BEniversitaire Ziekenhuizen Leuven873
招募中
1 期
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastases.Oligorecurrent hormone-sensitive prostate cancer patientsCTIS2022-502373-42-00Z Leuven873
尚未招募
2 期
Treatment of limited Oligo Metastatic disease in Esophageal and Stomach carcinoma; TOMES trialstomach and esophagus cancerupperGi cancer10017990NL-OMON52125Antoni van Leeuwenhoek Ziekenhuis73
招募中
3 期
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate CancerCastration-resistant Prostate CancerOligoprogressiveNCT06585007Universitaire Ziekenhuizen KU Leuven246
招募中
1 期
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANColigometastatic pancreatic cancerCTIS2023-503558-10-00niversitaetsmedizin Goettingen425